Systemic Inflammation and Evidence of a Cardio-splenic Axis in Patients with Psoriasis

Kasper F. HJULER1, Lars C. GORMSEN2, Mikkel H. VENDELBO2, Alexander EGEBERG1, Jakob NIELSEN1 and Lars IVERSEN1
Departments of 1Dermatology and 2Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, and 3Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark

The spleen is thought to play a role in atherosclerosis-associated immunity and cardiovascular research has indicated the existence of a cardio-splenic axis. The aim of this study was to assess splenic 18F-fluorodeoxyglucose uptake as a measure of systemic inflammation in patients with untreated psoriasis compared with historical controls assessed by positron emission tomography-computed tomography. Patients with moderate-to-severe psoriasis (n = 12, age 61.4 ± 4.1 years, 83% men, mean Psoriasis Area Severity Index score of 14.5) and controls (n = 23, age 60.4 ± 4.5 years, 87% men) were included in the study. Splenic inflammation was measured using the background-corrected spleen-liver-ratio (SLR) based on mean standardized uptake values. Mean ± SD SLR was increased in patients with psoriasis compared with controls (0.94 ± 0.11 vs. 0.82 ± 0.08; p = 0.001). SLR was significantly associated with aortic inflammation. These results support the existence of systemic inflammation in patients with psoriasis, and provide the rationale for a mechanistic link between psoriasis-driven inflammation and cardiovascular comorbidity through a spleen-atherosclerotic axis.

Key words: positron emission tomography computed tomography; inflammation; spleen; psoriasis; vascular inflammation; atherosclerosis.

Accepted Dec 20, 2017; Epub ahead of print Dec 20, 2017
Corr: Kasper F. Hjuler, Department of Dermatology, Aarhus University Hospital, P.P. Orums Gade 11, Bldg. 15, DK-8000 Aarhus C, Denmark. E-mail: kasperfjellhaugenjhu@gmail.com

Psoriasis is a common immune-mediated inflammatory disease that affects the skin, nails and joints. However, in recent years the disease has also been linked (directly or indirectly) to a host of comorbidities, with a strong focus on cardiovascular comorbidities. For example, psoriasis has been associated with an increased prevalence of all traditional cardiovascular risk factors (1), with premature coronary artery disease (2), and an increased risk of major adverse cardiovascular events and cardiac mortality (3, 4). Exploratory studies indicate shared immunological mechanisms in psoriasis and atherosclerosis (5, 6). Furthermore, patients with psoriasis exhibit increased inflammation of the aortic wall (7–9). In addition, it has been hypothesized that an increased systemic inflammatory load in patients with psoriasis, at least in part, causes premature atherosclerotic disease (10). Some studies show evidence of systemic inflammation in psoriasis, whereas other studies rebut these findings (11). A recent meta-analysis of soluble biomarkers of systemic inflammation shows evidence of mild systemic inflammation in patients with psoriasis compared with healthy control subjects (12). Taken together, it remains unclear to which extent psoriasis causes systemic inflammation, whether this is clinically relevant and if it is causally associated with premature development of cardiovascular disease.

Since the approval of the first commercial system in 2001, 18F-fluorodeoxyglucose-positron emission tomography computed tomography (FDG-PET/CT) has become a valuable imaging method in oncology. In addition, this modality is increasingly being used as an imaging tool for inflammatory conditions in general. Given the focus on inflammation in vascular plaque formation, FDG-PET/CT imaging has been investigated as an imaging tool in atherosclerosis (13), and it has been shown that FDG accumulation correlates with atherosclerotic plaque inflammation (14, 15). Preliminary insights indicate an association between FDG uptake in the vascular wall and increased risk of future cardiovascular events (16, 17). In addition, splenic inflammation can be visualized by FDG-PET/CT. Splenic FDG uptake is increased in inflammatory, malignant and infectious diseases, and the spleen-to-liver ratio (SLR) correlates with the peripheral neutrophil count (18–22). As shown in a human autopsy study, the spleen may play a role in activating and directing monocytes to the heart following ischaemic events (23). Furthermore, it has been shown that the activation state of the spleen may be closely related to proinflammatory gene activation within circulating leukocytes and that splenic FDG uptake independently predicts the risk of cardiovascular events (24). Based on preclinical and clinical data, a central role of the spleen in the progression of atherosclerotic disease has been suggested and conceptualized as the “cardio-splenic axis” (24–26). This concept entertains the hypothesis of a spleen-atherosclerotic plaque crosstalk.

We recently showed that aortic inflammation and subcutaneous adipose tissue inflammation, assessed by FDG-PET/CT, are significantly increased in patients with psoriasis compared with control subjects (9). The primary objective of the present study was to expand on these findings by assessing splenic FDG uptake as a measure of systemic inflammation in the same cohorts of patients with psoriasis and control subjects. A secondary objective was
to investigate whether splenic inflammation is associated with aortic and subcutaneous adipose tissue inflammation.

MATERIALS AND METHODS

Design and protocol

The study was designed as an open-label, controlled clinical study. We utilized a previous study cohort, established between January 2015 and May 2016 at a single tertiary dermatology university hospital clinic (9). Imaging investigations were performed at a university hospital nuclear medicine PET centre.

Consecutively enrolled patients with moderate-to-severe psoriasis were examined with FDG-PET/CT and compared with a retrospectively age- and sex-matched control group.

The study was conducted in compliance with the principles of the Declaration of Helsinki. The protocol was reviewed and approved by the Central Denmark Region Committees on Biomedical Research Ethics and by the Danish Data Protection Agency. All consecutively enrolled participants provided written informed consent prior to any study procedures. The Committee on Research Ethics waived the requirement for informed consent regarding the retrospectively matched control group.

Study population: patients with psoriasis and controls

Details of the inclusion and exclusion criteria have been described previously (9). Briefly, patients aged between 50 and 70 years with moderate-to-severe psoriasis vulgaris, i.e. a Psoriasis Area Severity Index (PASI) score of at least 10, were eligible for study inclusion if they had no concurrent inflammatory or autoimmune diseases, no history of malignancies within the past 5 years (excluding localized non-melanoma skin cancer) and no contraindications for the clinical use of FDG-PET/CT. Where appropriate, patients with psoriasis were entered into a pre-study washout period, where-in all active anti-psoriatic topical and systemic therapies were discontinued according to pre-specified time frames. The control group comprised age-matched men and women aged ≥18 years who were examined at the same centre, using the same technique as that employed for the study cases. The control subjects were either patients with localized melanoma or patients with localized stage 1 penile cancer. Additional eligibility criteria and details on clinical assessments are shown in Appendix S1.

Positron emission tomography acquisition

Whole-body FDG-PET/CT in patients with psoriasis was performed using a combined PET/CT scanner (GE Discovery 690, General Electric Medical Systems, Milwaukee, WI, USA). Control subjects were either scanned on the same GE Discovery 690 PET/CT or on a Siemens Biograph 64 PET/CT (Siemens, Germany).

A detailed description of the scan parameters is provided in Appendix S1.

Image analysis

PET and CT data were fused and analysed with PMOD v3.703 (PMOD Technologies, Zurich, Switzerland). CT and PET images were reviewed for quality, and the images were manually co-registered to ensure optimal anatomical correlation. Image analysis was performed in accordance with recent nuclear medicine imaging guidelines by one expert observer (L.C.G.).

In accordance with previously published methodology the splenic volume was assessed in each CT examination by measuring:

the maximal width of the spleen, determined as the largest diameter on any transverse section; the maximal thickness, defined as the largest distance between the inner and outer borders of the spleen perpendicular to the plane of the maximal width; and the thickness at the hilum, determined as the distance between the inner and outer borders of the spleen on a plane perpendicular to the splenic width and through the hilum (27).

Splenic inflammation was measured using mean standardized uptake values (SUVmax) and maximal standardized uptake values (SUVmax) and the SLR in accordance with current recommendations and previously published methodology (18, 21, 22, 26). Spleen volume of interest (VOIs) were drawn on 5 adjacent axial slices covering the central part of the organ, whereas liver VOIs were drawn on 6 adjacent axial slices in the right lobe (Fig. 1). Vascular inflammation was measured using aortic SUVmax and the target-to-background ratio (TBRmax) of the whole vessel and aortic segments in accordance with recent nuclear medicine imaging guidelines (13) and previously published methodology (9, 28). The TBR was calculated from the ratio of the SUV of the aorta compared with background venous activity, derived from the superior vena cava, for correction of aortic values.

Subcutaneous adipose tissue inflammation was assessed as SUVmax. A detailed description of the aortic wall and subcutaneous adipose tissue image analyses has been published previously (9).

Statistical analysis

Summary statistics were expressed as mean ± standard deviation (SD) for normally distributed variables. Patient characteristics were compared using Student’s t-test for continuous variables and Pearson’s χ² for categorical variables. The primary outcome measure was the mean difference in SLR between the patients with psoriasis and the control group. Between-group differences were compared using the unpaired t-test with equal variances. A multivariate analysis of covariance (ANCOVA) was performed as a secondary analysis to test the effect of the continuous covariates of age and body mass index (BMI) and categorical variable sex on difference in SLR.

Associations were tested using Pearson’s correlation coefficient. Data were tested for normality using the D’Agostino-Pearson normality test (see Appendix S1 for details). The level of statistical significance was set at α=0.05. Graphs and statistical analyses were made in GraphPad Prism version 7.0 (GraphPad software, San Diego, CA, USA) and STATA/IC ver. 12.1 for Mac (StataCorp LP, College Station, TX, USA).

![Fig. 1. Coronal and transverse PET images with volume of interests drawn in the spleen and the liver in a representative patient with psoriasis. Arrows indicate the region of interest in the spleen, liver, and aorta.](https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-2873)
Table I. Patient characteristics

<table>
<thead>
<tr>
<th>Variable</th>
<th>Psoriasis (n = 12)</th>
<th>Controls (n = 23)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, mean ± SD^a</td>
<td>61.4 ± 4.1</td>
<td>60.4 ± 4.5</td>
<td></td>
</tr>
<tr>
<td>Men, n (%)^a</td>
<td>10 (83)</td>
<td>20 (87)</td>
<td></td>
</tr>
<tr>
<td>Psoriasis Area Severity Index, mean ± SD^a</td>
<td>14.5 ± 4.3</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Disease duration, years, mean ± SD^a</td>
<td>35.9 ± 17.9</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Body Mass Index, kg/m^2, mean ± SD^a</td>
<td>29.3 ± 5.3</td>
<td>26.5 ± 4.4</td>
<td></td>
</tr>
<tr>
<td>Blood glucose, mmol/l, mean ± SD^a</td>
<td>6.8 ± 1.4</td>
<td>6.2 ± 0.9</td>
<td></td>
</tr>
<tr>
<td>Medically treated diabetes, n (%)^a</td>
<td>4 (33)</td>
<td>5 (22)</td>
<td></td>
</tr>
</tbody>
</table>

^aBaseline data were published previously (9). There were no significant differences between the groups at baseline except for spleen volume of interest (VOI) (p = 0.0002), liver VOI (p = 0.02), and subcutaneous adipose tissue (SAT) VOI (p = 0.0001). SD: standard deviation.

RESULTS

Included in the study were 12 subjects with moderate-to-severe psoriasis and 23 controls. Table I shows the characteristics of the included study subjects. The mean ± SD splenic total volume was slightly higher, albeit insignificantly so, among psoriasis patients compared with controls (269.5 ± 95.6 cm³ vs. 224.5 ± 62.8 cm³; p = 0.11).

Further imaging analyses are shown in Table II. FDG uptake in aortic segments and subcutaneous adipose tissue has been published previously (9). Mean SLRmax was increased in patients with psoriasis compared with controls (mean ± SD SLR 0.94 ± 0.11 vs. 0.82 ± 0.08; p = 0.001 (Fig. 2).

A significant association between SLR and aortic mean whole vessel TBRmax was found in the populations overall (Pearson r = 0.43; p = 0.01), but no significant associations were found in either of the specific groups (Fig. 3B). No significant association was found between PASI score and SLR (Pearson r = –0.42; p = 0.18)

Table II. ^18^F-fluorodeoxyglucose-positron emission tomography/computed tomography imaging results

<table>
<thead>
<tr>
<th>Variable</th>
<th>Psoriasis (n = 12)</th>
<th>Controls (n = 23)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUVmax mean ± SD^a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Entire aorta</td>
<td>4.01 ± 0.83</td>
<td>3.31 ± 0.56</td>
<td>0.005</td>
</tr>
<tr>
<td>Spleen</td>
<td>3.27 ± 0.63</td>
<td>3.01 ± 0.56</td>
<td>0.221</td>
</tr>
<tr>
<td>Liver</td>
<td>3.64 ± 0.54</td>
<td>3.95 ± 0.69</td>
<td>0.184</td>
</tr>
<tr>
<td>Subcutaneous adipose tissue^a</td>
<td>0.78 ± 0.26</td>
<td>0.40 ± 0.16</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>SUVmean mean ± SD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Entire aorta</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Spleen</td>
<td>2.12 ± 0.32</td>
<td>1.93 ± 0.34</td>
<td>0.127</td>
</tr>
<tr>
<td>Liver</td>
<td>2.27 ± 0.34</td>
<td>2.37 ± 0.45</td>
<td>0.530</td>
</tr>
<tr>
<td>Subcutaneous adipose tissue</td>
<td>0.21 ± 0.03</td>
<td>0.21 ± 0.07</td>
<td>0.938</td>
</tr>
<tr>
<td>Aortic TBRmax mean ± SD^a</td>
<td>2.46 ± 0.31</td>
<td>2.09 ± 0.36</td>
<td>0.005</td>
</tr>
<tr>
<td>SLRmean mean ± SD</td>
<td>0.94 ± 0.11</td>
<td>0.82 ± 0.08</td>
<td>0.001</td>
</tr>
<tr>
<td>SLRmax mean ± SD</td>
<td>0.90 ± 0.12</td>
<td>0.76 ± 0.11</td>
<td>0.003</td>
</tr>
</tbody>
</table>

^aAs previously published (9). Between-group differences were compared using the unpaired t-test with equal variances. NA: not available; SD: standard deviation; SLR: spleen-liver ratio; SUV: standardized uptake values; TBR: target-to-background ratio.

Fig. 2. Mean spleen-liver ratio based on mean standardized uptake values (SUVmean) in psoriasis and control subjects. The lines indicate median values, and the boxes extend from the 25th to 75th percentiles. The whiskers indicate min to max range. The mean is indicated by “+”.

Fig. 3. Correlation between FDG uptake in spleen, arterial wall and subcutaneous adipose tissue. (A) Association between spleen-liver ratio based on mean standardized uptake values and aortic mean whole vessel target-to-background ratio among subjects with psoriasis and controls. Pearson r = 0.51; p = 0.002. (B) The association between spleen-liver ratio based on mean standardized uptake values and subcutaneous adipose tissue inflammation among psoriasis subjects and controls. Pearson r = 0.43, p = 0.01. Symbols represent individual patients and the line represents the linear association between variables.
or between psoriatic disease duration and SLR (Pearson
\( r = 0.40; p = 0.20 \)).

After adjusting for BMI, age and sex using a multi-

DIVERSE ANCOVA regression model, psoriasis remained

significantly associated with elevated SLR levels (F = 3.79,

\( p = 0.01 \)). Furthermore, no difference was seen between

PET investigations in controls using GE Discovery 690

PET/CT vs. Siemens Biograph 64 PET/CT (mean ± SD

SLR\(_{\text{mean}}\) 0.81 ± 0.07 vs. 0.83 ± 0.09;\( p = 0.60 \)).

**DISCUSSION**

This is the first clinical study to show increased splenic

inflammation in patients with moderate-to-severe psoriasis

compared with control subjects. It also shows that splenic

inflammation is associated with aortic inflammation

in patients with psoriasis. Taken together with our previous

findings of increased global arterial and subcutaneous

adipose tissue inflammation in this cohort, these data pro-

vide evidence to support a role of systemic inflammation

and a likely role of an interplay between the spleen and

atherosclerotic plaque in patients with psoriasis.

The hypothesis that psoriasis may be a systemic in-

flammatory disease rather than a localized disease of the

skin and nails has gained much attention in recent years,

but the concept rests mainly on evidence from soluble

blood biomarker studies and on deductive reasoning

based on observational registry data (29). Most published

studies on soluble biomarkers indicate a moderate role

of systemic inflammation in psoriasis (1, 12). However,

these studies have a number of limitations in addition

to unknown predictive values and the non-specificity

certain biomarkers. Nevertheless, systemic inflammation

in psoriasis has become a key suspected culprit in

the link between psoriasis and cardiovascular comorbidities,

as well as in the reasoning on the role of psoriasis as

an independent risk factor for future cardiovascular events

that is seemingly unrelated to the traditional cardiovas-

cular risk factors. Although this hypothesis has gained

considerable momentum, the reported cardiovascular

effects of dampening the systemic inflammation with

leukocyte homeostasis and plays important roles in the immunological system.

Leukocytes in the spleen include various subsets of T and

B cells, dendritic cells and macrophages that initiate and

control innate and adaptive immune functions.

It has been shown that splenic inflammation assessed

by FDG-PET/CT is increased in patients with autoim-
mune and inflammatory diseases, and that the splenic

FDG uptake correlates with measures of systemic inflamma-

tion (18–22). Furthermore, studies in murine models

indicate a role of the spleen in atherosclerosis-associated

immunity (25, 37). Human proof-of-concept studies show

increased levels of splenic FDG uptake in patients with

recent myocardial infarction and an association between

spleen and arterial inflammation (38, 39). Emami et al.

showed that aortic wall FDG uptake correlated with splenic

FDG uptake in a large number of patients (\( n=464 \)).

Moreover, in this study splenic FDG uptake appeared

to be a predictor of future cardiovascular events. Taken

together with the correlation between splenic and aortic

inflammation, this entails that not only does the spleen

react acutely to myocardial infarction, but it also appears

to drive cardiovascular inflammation in a stable setting

(24, 26). Thus, the results of the current study corroborate

the existence of systemic inflammation in psoriasis beyond

that ascertained in previous biomarker studies, and the

current study provides the rationale for a mechanistic link

between psoriasis-driven inflammation and cardiovascular

comorbidity through a spleen-atherosclerotic axis.

In addition, we observed an increased volume of the

spleen in patients with psoriasis compared with controls,

albeit insignificantly so. Thus, a recent publication de-

scribed increased spleen longitudinal diameter in patients

with psoriasis compared with non-psoriatics, as well as an

association between disease duration and splenic diameter

(40). While this publication provided important quantative

analyses of the spleen in psoriasis, our study extends these

findings by providing functional imaging analysis, which

quantifies the metabolic activity of the spleen.

Interestingly, we found no association between PASI

scores and splenic inflammation. Hypothetically, a dose-

response relationship between psoriasis severity and the

inflammatory activation state of the spleen would be

plausible. The absence of such correlation in our data may

be due to the low variation in PASI scores and the limited

number of subjects investigated. Another reason may be

that PASI is not an optimal instrument for assessment of

systemic inflammation in patients with psoriasis (41).

This viewpoint is supported by the fact that studies with

cardiovascular and systemic inflammatory outcomes show

conflicting results when assessing the association with

PASI (2, 8, 9, 31, 42, 43).
These findings are strengthened by the use of background-corrected ratios TBR and SLR rather than SUV. Thus, the use of a ratio between 2 measurements limits the effects on signal quantification of errors in patient weight and in the dose of radiotracer injected and of the imaging time-point (13). It has been shown that exclusive use of SUV does not reliably reflect tissue metabolic activity and that, especially, correlations between SUV in various tissues should be interpreted with caution due to a positive correlation between SUV and body weight (26, 44). Thus, and in agreement with recent literature (26), SLR and not SUV was the primary outcome measure in this study. Further methodological strengths of the present study include our use of robust splenic and liver SUV mean values, which reduces the risk of measurements based on single high pixel values; the analysis of the entire aorta without sampling of slices; the inclusion of untreated psoriasis patients with moderate-to-severe disease activity only; and the use of semi-automatic software for image analysis, which makes the results reproducible with a low risk of biased assessments. The findings remained significant after adjusting for age, sex and BMI.

The main limitations of the study include the small sample size, the open-label design, restricted age groups due to radiation exposure, and the use of historical control sample size, the open-label design, restricted age groups due to radiation exposure, and the use of historical control sample size, the open-label design, restricted age groups due to radiation exposure, and the use of historical control sample size. In addition, 2 PET/CT systems were used. Comparable protocols were used, however, and no significant differences between results obtained from the 2 systems were noted.

Finally, although compelling interrelationships were observed between splenic activation and arterial inflammation, these relationships do not necessarily indicate causality.

In conclusion, our data provide evidence of increased splenic inflammation in subjects with moderate-to-severe psoriasis. Furthermore, we show that splenic activity correlates with aortic wall inflammation in subjects with psoriasis. These findings indicate clinically relevant systemic inflammation in patients with moderate-to-severe psoriasis. The cardio-splenic axis may mechanistically, at least in part, explain the epidemiological observation that patients with psoriasis have an increased risk of heart disease.

ACKNOWLEDGEMENTS

Funding: This study was supported by a grant from Pfizer (grant number WS2640077). Pfizer had no influence on the design of the study, the collection of data, the interpretation of the results, the preparation of the manuscript or the decision to submit for publication.

Disclosures: KFH reports research funding from AbbVie and honoraria as a consultant and/or speaker from AbbVie, Novartis and Eli Lilly; and travel grants from AbbVie, LEO Pharma, and Novartis, all unrelated to the submitted work. AE has received research funding from Pfizer and Eli Lilly, and honoraria as a consultant and/or speaker from Pfizer, Eli Lilly, Novartis, Galderma and Janssen Pharmaceuticals, and was previously employed by Pfizer. JN was employed according to the listed affiliation during all study activities except during the critical review process, at which time he was employed by Leo Pharma. LI reports grants from AbbVie, Pfizer and Novartis; and has served as a consultant and/or a paid speaker for and/or participated in clinical trials sponsored by: Abbvie, Almirall, Amgen, Celgene, Centocor, Eli Lilly, Janssen Cilag, Leo Pharma, MSD, Novartis, Pfizer and UCB, all unrelated to the submitted work.

REFERENCES

Cardio-splenic axis in patients with psoriasis


Cardio-splenic axis in patients with psoriasis